Status:
COMPLETED
Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
Lead Sponsor:
University of Cologne
Conditions:
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
Eligibility Criteria
Inclusion
- lymphocyte predominant Hodgkin´s lymphoma (histologically proven)
- clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR \> 50mm/h)
- age 18 - 75
- WHO performance status 0-3
- normal organ function
- written informed consent
Exclusion
- classical Hodgkin´s lymphoma
- composite lymphoma
- leucocytes \< 3000/µl
- thrombocytes \< 100.000/µl
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00346684
Start Date
July 1 2006
Last Update
August 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cologne
Cologne, Germany, 50931